Advanced Chemistry Development Enters Into Worldwide License Agreement with Pfizer for ACD/PhysChem Software
TORONTO - Feb 6, 2001 - Advanced Chemistry Development, Inc. (ACD) today announced that Pfizer, Inc. and ACD have signed a five-year agreement that will provide Pfizer scientists worldwide with critical predictive information about the physical properties of drug candidates.
Under the terms of the agreement, Pfizer will have unlimited desktop access to four ACD products, in order to provide every medicinal chemist with ready information about the physical properties of compounds while they are being considered for synthesis. The four products, which include LogD Suite, pKa DB, LogP DB, and Solubility Pro can be used at several levels of research including compound selection, parallel synthesis planning, medicinal chemistry, and formulation. Information about each of these products is available on-line at http://www.acdlabs.com/products/phys_chem_lab/.
Because compounds are typically not neutral, their physical properties (solubility, lipophilicity) depend on the pH (acidity) of their environment.. During absorption in the gastrointestinal tract, pH ranges from 1 to 8, a range in which most drug candidates' physical properties change by several orders of magnitude. Therefore, knowledge of a compound's pKa values and the dependence of other properties on pH are critical to understanding how a compound might be absorbed by patients.
"The mission of ACD's PhysChem software is to enable every medicinal chemist to make enlightened decisions about compounds they are planning to make. Understanding the likelihood of human absorption for compounds before they are synthesized is key to avoiding fruitless compounds and red-herrings in the lead optimization process," said Robert DeWitte, Ph.D., Scientific Product Manager for Physical Chemistry at ACD. "We are excited that Pfizer shares this vision and has chosen to join several other leading Pharma who have made this significant step." In addition, as a result of extensive collaboration with Pfizer, ACD has implemented enhanced versions of its software that seamlessly integrate with MDL ISIS software. "The integration of ACD software with ISIS provides easy-to-use accessibility to our PhysChem products," said Tim Blacker, Director of Sales at ACD. "Pfizer chemists can now obtain accurate and insightful predicted physical property prediction data - we think this is a significant added value to companies with a large investment in ISIS."
Advanced Chemistry Development, Inc. is a leader in the field of physical property prediction, desktop chromatography and spectroscopy management, systematic naming, and Web-based access to chemistry prediction. Founded in 1993 and with headquarters in Toronto, Canada, the company employs over 90 people and has established worldwide distribution channels. ACD's mission is to define a new standard in capability for chemistry-based software, addressing the needs of spectroscopy, chromatography, physical property prediction, and chemical naming.
Other Press Releases with Pfizer
|
